CNS & Neurology Commercial Advisory

Neuroscience strategy.
From biology
to market reality.

Senior strategic advisory for neurology and CNS companies navigating the gap between clinical proof and commercial success. Twenty years of VP-level experience across the full development and commercial lifecycle.

Disease Areas Migraine & Cluster Headache Post-Traumatic Headache Multiple Sclerosis Parkinson’s Disease Alzheimer’s Disease Huntington’s Disease Rare Epilepsy

Let’s discuss
your asset

Whether you’re preparing for Phase 2, navigating a competitive inflection, or defining the commercial strategy for a CNS asset — a focused conversation costs nothing.

tomas@boeckxadvisory.com linkedin.com/in/tomas-boeckx-112a43b Brussels, Belgium
Tomas Boeckx
Tomas Boeckx
MBA · Founder & Lead Advisor
Email LinkedIn
About

Senior judgment.
Direct engagement.

Boeckx Neuroscience Advisory brings VP-level commercial expertise directly to each engagement. Every analysis, every client interaction, every strategic recommendation delivered personally — the advisor you hire is the one who does the work.

Twenty years across the full spectrum of CNS — from pre-clinical pipeline valuation and Phase 2 commercial strategy through to global launch execution and lifecycle management. Deep experience across speciality neurology, rare disease, and neuroinflammation, spanning the US, EU, and Asia.

Career
2020 – 2025
VP Commercial & Corporate Strategy Neurology
Lundbeck · Copenhagen, Denmark
2019 – 2020
VP New Product Planning Psychiatry
Lundbeck · Copenhagen, Denmark
Apr – Dec 2018
VP Global Marketing, Migraine & Headache
Teva Pharmaceuticals · Amsterdam
2016 – 2018
VP Head of CNS Europe
Teva Pharmaceuticals · Amsterdam
2013 – 2016
European Brand Lead, Copaxone®
Teva Pharmaceuticals · Amsterdam
2011 – 2013
Business Unit Director CNS & Women’s Health
Teva Pharma Belgium
2007 – 2010
Product Manager BeNeLux Neurology (Rebif)
Merck Serono · Belgium
2006 – 2007
Key Account Manager Neurology
Merck Serono · Belgium
2004 – 2006
Sales Representative — Primary Care
Janssen-Cilag / Johnson & Johnson · Belgium
2003 – 2004
Sales Representative — Primary Care
Innovex for Eli Lilly · Belgium
1998 – 2001
Regional Area Manager France
Sportura Travel · BeNeLux
Education
2009 – 2011
MBA — International General Management
Vlerick Leuven Gent Management School
2001 – 2003
Master in Business Planning
Vlekho Business School · Brussels
1995 – 1998
Bachelor in Communication Management
Ham-Hogeschool · Mechelen
Board Membership
2013 – 2019
Independent Board Member
NVISO Security · Brussels — Pure-play cyber security firm (nviso.be)
Languages
Fluent
Dutch · English · French
Notions
German · Spanish

Get in touch

Available for focused engagements across CNS and neurology — asset positioning, competitive landscape, or commercial opportunity analysis.

tomas@boeckxadvisory.com linkedin.com/in/tomas-boeckx-112a43b Brussels, Belgium
Services

What we
do

Engagements are scoped to the question at hand. Every project is built around your specific asset, stage, and decision — not a standard template.

Competitive & Landscape Assessment

Systematic review of marketed therapies, pipeline classification, and unmet need mapping across relevant CNS segments. Mechanism-of-action differentiation and competitive gap analysis.

Delivered as a concise strategic brief. The focus is on what the competitive landscape means for your asset — not a catalogue of every drug in the space.

Market Opportunity & Commercial Modelling

Market sizing across US and EU5, growth driver analysis, and scenario-based revenue modelling with explicit assumptions. Built to inform decisions — not to produce a number that flatters the asset.

All commercial outputs are directional. The assumptions register is always included so you can update the model as clinical data matures.

Asset Positioning & Value Proposition

Target product profile definition, head-to-head differentiation logic, and a three-stakeholder value proposition framework for HCPs, payers, and patients.

Grounded in what the data can support. The output is a positioning options assessment with a clear recommendation — not a menu of possibilities to choose from.

Pipeline Valuation & BD Support

Commercial lead for in-licensing, acquisition, or partnership assessments in CNS and neurology. Commercial assessment of pipeline assets across pre-clinical to Phase 3.

Experience from both sides of the table — including commercial lead for the Alder Bio acquisition into Lundbeck ($2B), Longboard Pharmaceuticals ($2.3B), and the Labrys/fremanezumab deal at Teva ($1B).

How I
work
Every engagement is led personally by Tomas Boeckx. No account managers, no handoffs. The advisor you brief is the one who does the analysis and presents the findings.
Scope is agreed upfront and respected. If the engagement needs to evolve, it is raised explicitly and agreed in writing before proceeding — not discovered at the final readout.
Outputs are directional and honest about uncertainty. The goal is to give you the clearest possible strategic picture, including what we know, what we are estimating, and what genuinely remains open.

Discuss an engagement

If you have a specific question about your asset or would like to discuss how an engagement could be structured, get in touch directly.

tomas@boeckxadvisory.com linkedin.com/in/tomas-boeckx-112a43b Brussels, Belgium